ASML Holding (NASDAQ: ASML) remains a key player in the semiconductor industry, reporting 7.5 billion euros in net sales and 2.1 billion euros in net income in Q3. With the commercial rollout of the High-NA EUV lithography system on the horizon, ASML anticipates increased demand and revenue growth. Intel and SK hynix have already started installing these systems, with more orders expected from 2026 onwards.

Eli Lilly (NYSE: LLY) has seen a surge in revenue and earnings, driven by its obesity and type 2 diabetes drug portfolio. The company’s GLP-1 drug, tirzepatide, has gained significant market share, positioning Eli Lilly for further growth in the global GLP-1 drug market. The upcoming launch of Orforglipron could provide another boost to the company’s offerings.

For investors looking to generate long-term returns, investing in ASML or Eli Lilly could be a wise choice. Both companies are poised for growth and have strong market positions in their respective sectors. ASML’s technological advancements and Eli Lilly’s innovative drug portfolio make them attractive options for investors with $5,000 to spare.

Read more at Yahoo Finance: Got $5,000? 2 Stocks to Buy Now and Hold for the Long Term